Aurinia Pharmaceuticals Inc. (AUPH) - 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Aurinia is a biopharmaceutical company focused on autoimmune diseases, primarily commercializing LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for active lupus nephritis (LN). The company also has a pipeline candidate, aritinercept, a dual BAFF/APRIL inhibitor. Aurinia markets LUPKYNIS directly in the U.S. and collaborates with Otsuka Pharmaceutical Co., Ltd. for commercialization in Japan, the E.U., and other territories.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $283.1 million | $235.1 million |
| Net Product Sales | $271.3 million | $216.2 million |
| Net Income | $287.2 million | $5.8 million |
| Operating Income | $104.9 million | ($4.7 million) loss |
| Cash Flow from Operations | $135.7 million | $44.4 million |
| Cash & Investments | $398.0 million | $358.5 million |
| Gross Margin | 88% | 88% |
| Diluted EPS | $2.07 | $0.04 |
Debt & Liquidity: The company holds no traditional debt but has a finance lease liability of $68.8 million related to its dedicated manufacturing facility (Monoplant). Liquidity remains strong with $398.0 million in cash, cash equivalents, and investments.
Material Changes vs. Prior Period
- Profitability Surge: Net income increased from $5.8 million in 2024 to $287.2 million in 2025. This was primarily driven by a $173.0 million income tax benefit resulting from the release of the valuation allowance on deferred tax assets, as the company now expects to realize these assets.
- Revenue Growth: Net product sales grew 25% to $271.3 million, driven by increased market penetration of LUPKYNIS in the U.S. However, license, collaboration, and royalty revenue declined 38% to $11.7 million, largely due to the absence of a $10.0 million regulatory milestone payment received in 2024 for Japan approval.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses dropped significantly by $70.2 million (41%) to $101.8 million, attributed to strategic restructuring efforts in 2024 that reduced headcount and share-based compensation costs.
- Restructuring Costs: Restructuring expenses fell from $23.1 million in 2024 to $1.6 million in 2025, as the major restructuring initiatives were completed in the prior year.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects SG&A expenses in 2026 to remain consistent with 2025 levels. R&D expenses are expected to increase as development activities for aritinercept progress. The company plans to initiate a clinical study for aritinercept in an additional autoimmune disease in the first half of 2026.
Share Repurchases: In 2025, the company repurchased 12.2 million shares for $98.2 million. The Board previously authorized a $300 million repurchase program (increased by $150 million in July 2025).
Key Risks & Contingencies:
- Patent Litigation: Aurinia received Paragraph IV notices from eight generic manufacturers (including Hikma, Teva, and Sandoz) in early 2025 challenging the validity of patents expiring in 2037. Aurinia has filed infringement lawsuits against all parties. While Hatch-Waxman provides a 7.5-year exclusivity stay, litigation outcomes remain uncertain.
- Single Product Dependence: The business is substantially dependent on the commercial success of LUPKYNIS, its sole approved product.
- Supply Chain: Manufacturing relies on sole-source contract manufacturers (Lonza for drug substance, Catalent for encapsulation). Any interruption could materially impact sales.
- Regulatory & Pricing: The company faces ongoing pressure from government pricing reforms (e.g., Inflation Reduction Act) and potential changes in reimbursement policies.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the assumptions behind the release of the $173 million valuation allowance and the likelihood of realizing deferred tax assets in future periods.
- Patent Litigation Status: Monitor the progress of the eight patent infringement lawsuits filed against generic manufacturers and the potential impact on the 2037 patent exclusivity.
- Share Repurchase Impact: Assess the remaining capacity under the $300 million share repurchase program and its effect on future cash flow and liquidity.
- Aritinercept Development: Track the initiation and early results of the new clinical study for aritinercept planned for 2026.
- Customer Concentration: Note that two specialty pharmacies accounted for 87% of total revenue in 2025, creating significant concentration risk.